Primary neuroendocrine carcinoma of the breast - the report of four cases

Authors: Katarzyna Steinhof-Radwańska, Anna Barczyk, Piotr Powązka, Maciej Kajor, Zuzanna Dobrosz, Ewa Świątkowska-Szlachta, Joanna Pilch-Kowalczyk

DOI: 10.5603/EP.a2017.0049

Article type: Case report

Submitted: 2016-09-23

Accepted: 2016-10-27

Published online: 2017-09-04

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Endokrynologia Polska" are listed in PubMed. The final version may contain major or minor changes.
Primary neuroendocrine carcinoma of the breast — a report of four cases

Katarzyna Steinhof-Radwańska¹, Anna Barczyk¹, Piotr Powązka³, Maciej Kajor², Zuzanna Dobrosz², Ewa Świątkowska-Szalachta⁴, Joanna Pilch-Kowalczyk¹.

¹Zakład Medycyny Nuklearnej i Diagnostyki Obrazowej Katedry Radiologii i Medycyny Nuklearnej SUM

²Katedra i Zakład Patomorfologii SUM

³Centrum Diagnostyki i Terapii Onkologicznej Katowice ul. Ceglana 35, 40-514 Katowice

⁴Uniwersyteckie Centrum Kliniczne im. prof. K Gibińskiego Śląskiego Uniwersytetu Medycznego Oddział Chirurgii Onkologicznej

Address for correspondence: Joanna Pilch-Kowalczyk; Zakład Medycyny Nuklearnej i Diagnostyki Obrazowej ul. Ceglana 35, 40-514 Katowice; tel. 601521375; email: jpk@alteris.pl

Abstract

Breast neuroendocrine tumours are rare, accounting for up to 5% of all breasts tumours and approximately 1% of all neuroendocrine tumours. In most cases, breast neuroendocrine tumours are histologically and moderately well differentiated. Neuroendocrine breast tumours lack characteristic imaging patterns. The histopathological assessment of these tumours is
difficult, and in most cases the correct diagnosis is made after proper examination of the postsurgical specimen.

**Keywords:** neuroendocrine breast cancer

**Introduction**

Neuroendocrine tumours (NET) constitute a large and heterogeneous group of rare neoplasms with non-specific clinical symptoms, frequently originating from the GI tract (bowel and pancreas) and respiratory system [1, 2], and less frequent from endocrine glands (adrenals, thyroid, hypophysis, thalamus) [3]. The usual form is a singular lesion, and sporadically they contribute in MEN syndromes (multiple endocrine neoplasia).

The primary neuroendocrine tumours of the breast were not separately classified by the WHO until 2003 and account for 0.1% [4] to 5% [5, 6] of breast tumours and approximately 1% of all neuroendocrine tumours.

According to the WHO modification from 2012 [7, 8], neuroendocrine tumours are divided into the following groups: well differentiated, poorly differentiated (small cell), and cancers with neuroendocrine differentiation [4]. A local accumulation of neuroendocrine cells is present in many sub-types of breast cancers [9].

The definition of primary neuroendocrine breast tumour is reserved for cases with over 50% of neoplastic cells showing expression of the markers typical for these tumours: chromogranin and synaptophysin [9].

The majority of tumours are well or moderately differentiated. Over 50% of the poorly differentiated tumours are positive for oestrogen and progesterone receptors [7].
The differentiation between primary and secondary neuroendocrine carcinoma of the breast is possible only after the other primary site is excluded [4].

**Description of the cases**

**Patient no. 1**

A 65-year-old woman with palpable tumour of the left breast. In spectral mammography, there was an 8 x 4-cm mass with strong contrast enhancement in the in lower quadrants of the left breast. (Picture 1a, 1b). A BLESS biopsy under mammographic guidance revealed invasive ductal carcinoma G3. The patient underwent mastectomy, and the final pathology report revealed the neuroendocrine tumour with small foci of connective tissue infiltration (Picture 1c). The size of the tumour was 5 x 1.7 x 1.5 cm, and the tumour was positive for oestrogen and progesterone receptors, Her-2 negative, Ki 67 1%, synaptophysin (+), and chromogran (-). The axillary lymph nodes were negative.

**Patient no. 2**

A 77-year-old woman after positive FNA of the left breast under US guidance, referred for a mammography, which revealed and oval, 31 x 22-mm lesion with microlobular and somewhat spiculated margins in the upper outer quadrant of the left breast (Picture 2a, 2b). The core biopsy under US guidance revealed invasive ductal carcinoma. After the BCU meeting decision the patient was referred for a mastectomy. The pathologic examination revealed a grey, solid tumour 2.7 x 2 x 1.9 cm with final description as the neuroendocrine ductal carcinoma G2 (picture 2c — multifocal neuroendocrine tumour with infiltration on fat tissue H-E stain, Picture 2d — synaptophysin stain) with positive progesterone and oestrogen receptors, Her-2 negative, and Ki 67 positive in 10%. The axillary lymph nodes were negative.
**Patient no. 3.**

A 52-year-old woman with positive US examination of the left breast. The spectral mammography showed 3.9 x 2.2 cm strongly enhancing mass in the upper outer quadrant of the left breast. Behind the dominant mass the mammography revealed a second, similar but smaller 2.5 x 1.3-cm lesion (Picture 3a,3b). The core biopsy of the dominant mass revealed invasive ductal carcinoma G2. The patient underwent mastectomy, and the post-surgical diagnosis was invasive ductal carcinoma with focal neuroendocrine differentiation and focal mucinous differentiation (picture 3c - H-E stain, picture 3d synaptophysin stain). The cancer was positive for progesterone and oestrogen receptors, Her-2 negative, Ki67 positive in 15%, and synaptophysin positive. The axillary lymph nodes were negative.

**Patient no. 4.**

A 65-year-old woman with positive US examination of the left breast. The spectral mammography showed enhancing, spiculated tumour in the upper outer quadrant, measuring 2.5 x 2.2 cm, with intense desmoplastic reaction on the area of 3–3.5 cm. (Picture 4a, 4b). The core biopsy of the tumour, performed in a different hospital, showed invasive ductal carcinoma G2. The BCU meeting referred the patient for conserving breast treatment. The radiograph of the specimen (Picture 4c) shows the excised tumour. The final pathological diagnosis was neuroendocrine tumour NET G2 (Picture 4d) with positive progesterone and oestrogen receptors, Her-2 negative, Ki67 5%, synaptophysin (+), chromogranin (+), and serotonin (-). The axillary lymph nodes were negative.
Discussion

Primary neuroendocrine breast tumours are extremely rare, with no typical clinical symptoms, and the diagnosis of the primary tumour is always done by exclusion [4]. Older women, in their 60s and 70s, are more affected, commonly one decade later than invasive breast cancer [10]. From 10 to 50% of the breast tumours can contain dispersed singular neuroendocrine cells; it is important is to distinguish cancer with focal neuroendocrine differentiation from “proper” neuroendocrine tumours [5]. In the literature, there are no cases of benign neuroendocrine tumours of the breast [6], thus one hypothesis suggests that they originate as a result of the differentiation of the breast cancer and not directly from preserved endocrine cells [9].

Most neuroendocrine cells coexist with invasive ductal cancer or cancer with mucinous component, and typically tumours show expression of oestrogen and progesterone receptors (4.10)

The specific radiological symptoms are still questioned. According to Park [2], in mammographic evaluation the neuroendocrine tumour was most frequently described as a mass (82%) with no calcifications in 75% of cases. Most tumours were oval, round, or lobular (70%). In our material, three of the four lesions were morphologically similar and the margins were poorly defined. According to Park [2], spiculated margins, considered as a radiological sign of malignancy, were present only in 22% of lesions; similarly, in our cases only one in four had spiculated margins. However, in accessible case descriptions there are no specific features of NEC in the radiological imaging (6.10)

The retrospective analysis of a large group of patients (142 persons) performed by Wang et al. [10] revealed that neuroendocrine tumours at the time of the diagnosis are larger than invasive cancers (over 20 mm) and more frequently have metastases to the lymph nodes. In our material, the lesions were bigger than 2 cm in all four patients, but no preoperative FNA
showed dissemination to the lymph nodes, although all the patients were qualified for sentinel lymph node procedure. In histopathological material also no dissemination to lymph nodes was found. In every case, tests for hormonal receptors confirmed expression of PR and E receptors.

Neuroendocrine tumours and cancer with neuroendocrine differentiation according to WHO classification are included to the special sub-types of breast neoplasms. The pathologic assessment of neuroendocrine tumours can be challenging in cases where the material has been obtained by core biopsy. The morphological characteristics of the neuroendocrine cancer cell, especially of the pseudo adenomatous form, is very similar to invasive NST cancer. The assessment of hormone receptors and Her-2 protein carried out by core biopsy in invasive cancers adds no value to diagnosis because both NST G1/G2 and neuroendocrine tumours are hormonally positive and Her-2 negative. Positive Her-2 could indicate invasive NST cancer. The diagnosis of the neuroendocrine tumour is based on immunohistochemical positive reaction of chromogranin A and/or synaptophysin.

The finding in a postoperative specimen of solid or lobular foci arranged in nests entwined by a narrow layer of connective tissue with cells of bright cytoplasm and bright chromatin with nucleolus indicates suspicion of neuroendocrine tumour, requiring immunohistochemical confirmation.

The Ki 67 proliferative index allows differentiation of neuroendocrine tumours (Ki 67 up to 20%) from neuroendocrine cancers (Ki 67 over 20%).

Sometimes, poorly differentiated neuroendocrine breast cancer is morphologically very similar to small cell lung neuroendocrine cancer, and in those cases is called small cell neuroendocrine cancer.

It should not be forgotten that in some cases the breast is a metastatic destination for neuroendocrine cancer of the lung and GI tract. In such cases in the histopathological
examination, apart from positive neuroendocrine markers, positive antibodies CD56 (lung) and serotonin (GI tract) could be helpful. In the case of the papillary cancer the neuroendocrine markers could be also positive. In such cases neoplastic cells are small with hyperchromatic fusiform or multiform nuclei and lay in foci with intense desmoplastic reaction. The foci can be surrounded by a layer of myoepithelial cells. Steroid receptors are usually positive and Her 2-protein negative. Positive cytokeratin 8 and 18 can be helpful, but the morphology of the routinely stained sample decides on the final diagnosis of cancer. Neuroendocrine breast cancers are a small group of neoplasms with different degrees of malignancy, thus the prognosis differs. It should be noted that they can be primary or secondary. In order to establish proper diagnosis a multidisciplinary approach is mandatory, with a special role played by immunohistochemical tests.

References:


